Our Science
Developing novel solutions with pioneering science
PharmaEssentia is working to rewrite the paradigm of early treatment of myeloproliferative neoplasms (MPNs). Grounded in our scientific team’s deep expertise, our novel technology platform has the potential to redefine treatment approaches for a range of hematologic diseases by realizing the potential of proven hematology/oncology therapies.
In 2022, we were recognized as “Therapeutics Solution of the Year” by the BioTech Breakthrough Awards.